Last reviewed · How we verify
NCT03243773: ELUSIA
Evaluation of Lung Ultrasound in Acute Heart Failure
trial testing Lung ultrasound in Acute Heart Failure in 56 participants. Completed in 30 September 2018.
30 September 2018
Quick facts
| Lead sponsor | Prof. Dr. Jörg Leuppi |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 56 |
| Start date | 1 March 2016 |
| Primary completion | 30 September 2018 |
| Estimated completion | 30 September 2018 |
| Sites | 1 location across Switzerland |
Drugs / interventions tested
- Lung ultrasound
Conditions studied
- Acute Heart Failure — all drugs for Acute Heart Failure →
Sponsor
Prof. Dr. Jörg Leuppi
Who can join
18 and older, any sex, with Acute Heart Failure. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Acute heart failure is a life threatening condition requiring rapid diagnosis and treatment. However, the differentiation between heart failure and other conditions presenting with acute dyspnea is notoriously difficult in the emergency room. Point-of-care lung ultrasound is a simple, rapid and noninvasive technique directly visualizing fluid content in the lung as evidence for acute heart failure. A number of publications showed the diagnostic utility of lung ultrasound in the diagnosis of heart failure, but many open questions remain. The goal of this study is to evaluate the diagnostic accuracy of lung ultrasound to predict a cardiac origin of dyspnea in unselected patients in the emergency room as compared to standard evaluation. Further goals are to evaluate if lung ultrasound provides additional diagnostic information as compared to clinical examination, NT-proBNP and chest X-ray, to compare the diagnostic accuracy of lung ultrasound in different patient subgroups (heart failure with preserved vs reduced ejection fraction, de novo vs decompensated chronic heart failure, age ≥75 vs \<75 years, women vs men and presence vs absence of concomitant pulmonary disease) and to compare demographics and clinical characteristics in different patient populations. 300 patients, aged ≥18 years presenting to the emergency room (ER) with acute dyspnoe as principal complaint will undergo initial clinical assessment of the likely etiology of dyspnea by the ER physician in charge. The second assessment by the same physician will include results of NT-proBNP according to predefined cutoffs. Final diagnosis ("Gold Standard") will be done by two experienced investigators after patient discharge taking into account the complete medical record except the results of lung ultrasound. Assessment of chest X-ray and lung ultrasound by investigators will be preforemd blinded regarding all other results.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03243773
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Lung ultrasound
Trials testing the same drug.
- NCT07442669 — Utilization of Lung Ultrasound Score in Decision for Minimally Invasive Surfactant Administration · NA · not yet recruiting
- NCT07261956 — Lung Ultrasound for the Detection of Volume Overload in Patients With Severe Preeclampsia · NA · recruiting
- NCT06984120 — Increased Extravascular Lung Water in Asymptomatic Open-water Swimmers · completed
- NCT06965634 — Investigation of the Effectiveness of Lung Ultrasonography in Intraoperative Fluid Management · not yet recruiting
- NCT06584474 — THE EFFECT OF NEBULIZED AZITHROMYCIN AS THERAPY FOR BRONCHOPULMONARY DYSPLASIA · Phase 4 · completed
Other recruiting trials for Acute Heart Failure
Currently open trials in the same condition.
- NCT06587854 — a PRagmatic Observational Study of Congestion proFILes in patiEnts With Acute Heart Failure · recruiting
- NCT07008365 — The Role of intraABDOminal Pressure and Point Of Care UltraSound to Guide Decongestive Therapy in Heart Failure · Phase 3 · recruiting
- NCT06465498 — Investigating aCute heArt failuRe Decongestion Guided by Lung UltraSonography · NA · recruiting
- NCT06597331 — Cardiac Assessment and Takotsubo-stunning Among COPD-exacerbations In-Hospital · recruiting
- NCT06166654 — Optimal Diuretic Therapies for Acute Heart Failure With Volume Overload · Phase 4 · recruiting
Other Prof. Dr. Jörg Leuppi trials
Trials by the same sponsor.
- NCT04536350 — Inhaled Aviptadil for the Treatment of COVID-19 in Patients at High Risk for ARDS · Phase 2 · terminated
- NCT04525820 — High Dose Vitamin-D Substitution in Patients With COVID-19: a Randomized Controlled, Multi Center Study · NA · completed
- NCT03984253 — Swiss Severe Asthma Register · recruiting
- NCT04471610 — Point Of Care With Serial NT-proBNP Measurement in Patients With Acute Decompensation of Heart Failure · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03243773 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Prof. Dr. Jörg Leuppi
- Last refreshed: 19 September 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03243773.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing